Conquering the final frontier in lung transplantation - Mesenchymal stromal cell therapy for chronic lung allograft dysfunction [ 2016 - 2021 ]

Research Grant

Researchers: A/Pr Daniel Chambers (Principal investigator) ,  A/Pr Glen Westall ,  A/Pr Peter Hopkins ,  Prof Allan Glanville ,  Prof Mark Holmes

Brief description Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.

Funding Amount $AUD 1,955,312.71

Funding Scheme Project Grants

Notes Standard Project Grant